|Classification and external resources|
|Patient UK||Lennox–Gastaut syndrome|
Lennox–Gastaut syndrome (LGS), also known as Lennox syndrome, is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life, and is characterized by frequent seizures and different seizure types; it is often accompanied by developmental delay and psychological and behavioral problems.
- 1 Characteristics
- 2 Incidence and prevalence
- 3 Mortality
- 4 Causes
- 5 Diagnosis
- 6 Treatment
- 7 History
- 8 Support & Community
- 9 Resources
- 10 References
- 11 See also
|This section needs additional citations for verification. (April 2013)|
As a general rule, the age of seizure onset in LGS patients is between the ages of two and six; however, this does not exclude the possibility that seizures can begin before age two, or after age six. The syndrome shows clear parallels to West syndrome, enough to suggest a connection.
Daily multiple seizures are typical in LGS. Also typical is the broad range of seizures that can occur, larger than that of any other epileptic syndrome. The most frequently occurring seizure type is tonic seizures, which are often nocturnal (90%); the second most frequent are myoclonic seizures, which often occur when the person is over-tired.
Atonic, atypical absence, tonic, complex partial, focalized and tonic–clonic seizures are also common. Additionally, about half of patients will have status epilepticus, usually the nonconvulsive type, which is characterized by dizziness, apathy, and unresponsiveness. The seizures can cause sudden falling (or spasms in tonic, atonic and myoclonic episodes) and/or loss of balance, which is why patients often wear a helmet to prevent head injury.
In addition to daily multiple seizures of various types, children with LGS frequently have arrested/slowed psycho-motor development and behavior disorders.
Incidence and prevalence
LGS is seen in approximately 4% of children with epilepsy, and is more prevalent in males than females.  Children can have no neurological problems prior diagnosis, or have other forms of epilepsy. West syndrome is diagnosed in 20% of patients before it evolves into LGS at about 2 years old.
According to a 1997 community-based retrospective study in the Helsinki metropolitan area and the province of Uusimaa, the annual incidence of Lennox–Gastaut was 2 in 100,000 (0.002%) from 1975 to 1985.
0.026% of all children in the Atlanta, Georgia metropolitan area were estimated to have LGS in 1997, which was defined as, "onset of multiple seizure types before age 11 years, with at least one seizure type resulting in falls, and an EEG demonstrating slow spike-wave complexes (<2.5 Hz)." The study concluded that LGS accounts for 4% of childhood epilepsies.
The mortality rate ranges from 3-7% in a mean follow up period of 8.5 to 9.7 years. Death is often related to accidents.
The most common type of LGS (70–78%) is symptomatic (secondary) - that is an identifiable underlying pathology is responsible. This includes encephalopathy (brain damage) or another disease and/or developmental disorder. Frequent causes include tuberous sclerosis, hereditary metabolic diseases, inflammatory brain disease such as encephalitis, meningitis, and toxoplasmosis; hypoxia–ischemia injury and other birth injuries; and lesions of the frontal lobe. These patients tend to have a worse prognosis than those with idiopathic LGS.
In up to one-third of cases no cause can be found. These cases are referred as cryptogenic if a cause is suspected but unknown. Not all investigators mention the second category.
Lennox–Gastaut syndrome and drug resistant/drug refractory epilepsy have been recorded with neurovisceral porphyrias including acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. Care must be taken to avoid porphyrinogenic anti-seizure drugs in these cases. Diagnosis may be difficult in children who require enzyme or DNA testing.
|This section does not cite any references or sources. (April 2013)|
Generally speaking, LGS can often only be defined as a syndrome and/or distinguished from other syndromes because there are various overlaps with other syndromes. Currently, the fact that there is no uniform cause complicates things.
The diagnosis or suspicion of LGS is often a question of probability rather than certainty. This is because the varied presentations of LGS share features with other disorders, many of which may be said to have overlapping characteristics.
The diagnosis is more obvious when the epilepsy has frequent and manifold attacks, with the classic pattern on the electro-encephalogram (EEG); the latter is a slowed rhythm with Spike-wave-pattern, or with a multifocal and generalizing Sharp-slow-wave-discharges at 1.5–2.5 Hz. During sleep, frequently, tonic patterns can be seen. But variations of these patterns are known in patients with no diagnosis other than LGS, and they can differ bilaterally, and from time to time, within the same patient.
General medical investigation usually reveals developmental delay and cognitive deficiencies in children with true LGS. These may precede development of seizures, or require up to two years after the seizures begin, in order to become apparent.
Exclusion of organic or structural brain lesions is also important in establishing a correct diagnosis of LGS; this may require magnetic resonance imaging (MRI) or computerized tomography (CT). An important differential diagnosis is 'Pseudo-Lennox-Syndrome', which differs from LGS, in that there are no tonic seizures; sleeping EEG provides the best basis for distinguishing between the two.
LGS seizures are often treatment resistant, but this does not mean that treatment is futile. Options include anticonvulsants, anesthetics, steroids such as prednisone, immunoglobulins, and various other pharmacological agents that have been reported to work in individual patients.
No scientific study has shown any drug to be highly efficacious for treatment of LGS, and its best treatment remains uncertain. Rufinamide(Banzel), lamotrigine, topiramate and felbamate may help as add-on therapy.
Rufinamide approved recently by FDA
|This section does not cite any references or sources. (April 2013)|
- valproates (valproic acid, sodium valproate and valproate semisodium)
- benzodiazepines, specifically clonazepam, nitrazepam, and clobazam
Nitrazepam is not approved in the USA.
Clobazam has been recently approved by the FDA on 10/24/11.
In 1999, Dr. Sachdeo and colleagues at the University of Medicine and Dentistry of New Jersey and the Robert Wood Johnson Medical School in New Brunswick reported that 33% of the patients in the topiramate group experienced a minimum 50% reduction in seizures (specifically drop attacks and tonic–clonics), compared with 8% in the placebo group. It was also found to be effective as an adjunctive therapy in a review published by Drs. Edith Alva Moncayo and Antonio Ruiz Ruiz in March 2003.
Dr. Motte and colleagues at the American Memorial Hospital at Reims, France reported in 1997 that lamotrigine was effective in the treatment of LGS, with the most common side effect in the treatment group relative to placebo being colds or viral illnesses. Two years later, it was approved by Health Canada for adjunctive therapy in Lennox Gastaut in adults and children. The United States Food and Drug Administration approved it for that in August 1998.
Felbamate is indicated in the use of LGS in the event that everything else fails, and was found to be superior to placebo in controlling treatment resistant partial seizures and atonic seizures. However, it has been known to cause aplastic anemia and liver toxicity.
Unapproved, off-label, and investigational drugs
Vigabatrin was found by Feucht et al. to be an effective add-on in patients whose seizures were not satisfactorily controlled by valproate. Out of 20 children, only 1 experienced a serious side effect (dyskinesia).
Zonisamide showed promise in an overview of controlled and uncontrolled trials conducted in Japan. However, in a physician survey conducted December 2004, only 28% of Lennox–Gastaut and West syndrome patients improved on zonisamide.
Intravenous immunoglobulin therapy
Intravenous immunoglobulin therapy has been used in Lennox–Gastaut syndrome as early as 1986, when van Rijckevorsel-Harmant and colleagues used it in seven patients with ostensibly idiopathic LGS and saw EEG improvement and decreased seizure frequency in six of them.
In 2010 the first documentary highlighting this disorder was produced by Eisai Inc. in cooperation with the LGS Foundation.
Support & Community
Caregivers of individuals living with Lennox-Gastaut Syndrome may seek support and information from a variety of resources including the LGS Foundation and the Epilepsy Foundation of America. The LGS Foundation offers an international conference every 18 months in the United States, regional support groups, online support groups, and numerous other programs and services.
International LGS Awareness Day is November 1 annually.
- "Childhood seizures – epilepsy and convulsions in children". Archived from the original on April 8, 2005. Retrieved August 16, 2005.
- Trevathan, E; Murphy, CC; Yeargin-Allsopp, M (1997). "Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children". Epilepsia 38 (12): 1283–8. doi:10.1111/j.1528-1157.1997.tb00065.x. PMID 9578523.
- Tyagi, Satyanand et al. (Jul–Sep 2010). "Pharmacological Management of Lennox-Gastaut Syndrome a Difficult to Treat Form of Childhood-Onset Epilepsy: An Overview" (PDF). International Journal of Pharma and Bio Sciences 1 (3): 1–6.
- Heiskala, H (1997). "Community-based study of Lennox-Gastaut syndrome". Epilepsia 38 (5): 526–31. doi:10.1111/j.1528-1157.1997.tb01136.x. PMID 9184597.
- Glauser, Tracy A. and Morita, Diego A. (2002). "Introduction". Lennox–Gastaut Syndrome. eMedicine.com, Inc. Retrieved 8 July 2005.
- Lund C, Brodtkorb E, Øye AM, Røsby O, Selmer KK (2014). "CHD2 mutations in Lennox-Gastaut syndrome". Epilepsy Behav. 33: 18-21. doi:10.1016/j.yebeh.2014.02.005. PMID 24614520.
- LCapelli LP, Krepischi AC, Gurgel-Giannetti J, Mendes MF, Rodrigues T, Varela MC, Koiffmann CP, Rosenberg C (2012). "Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency". Eur J Med Genet. 55 (2): 132-134. doi:10.1016/j.ejmg.2011.10.004. PMID 22178256.
- Hancock, EC; Cross, HH; Hancock, Eleanor C (2009). Hancock, Eleanor C, ed. "Treatment of Lennox-Gastaut syndrome". Cochrane database of systematic reviews (Online) (3): CD003277. doi:10.1002/14651858.CD003277.pub2. PMID 19588340.
- Sachdeo, R. C.; Glauser, TA; Ritter, F; Reife, R; Lim, P; Pledger, G (1999). "A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome". Neurology 52 (9): 1882–7. doi:10.1212/wnl.52.9.1882. PMID 10371538.
- Alva-Moncayo, E; Ruiz-Ruiz, A (2003). "Utilidad del topiramato como terapia añadida a esquemas convencionales para el síndrome de Lennox-Gastaut" [The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox-Gastaut syndrome]. Revista de neurologia (in Spanish) 36 (5): 453–7. PMID 12640599.
- Motte, J; Trevathan, E; Arvidsson, JF; Barrera, MN; Mullens, EL; Manasco, P (1997). "Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group". The New England Journal of Medicine 337 (25): 1807–12. doi:10.1056/NEJM199712183372504. PMID 9400037.
- Epilepsy Ontario (1999). "Lamotrigine Approved in Canada for Lennox–Gastaut Syndrome". 'Sharing' News. Retrieved 13 November 2005.
- Glaxo Wellcome Inc (1998). "Final Printed Labeling—Part 1". Lamictal Tablets & Chewable Dispersible Tablets (Lamotrigine) Drug Approval Page. United States Food and Drug Administration Center for Drug Evaluation and Research. Retrieved 13 November 2005.[dead link]
- "Felbatol (felbamate)". p. 3. Retrieved 2007-09-19.
- The Felbamate Study Group In Lennox-gastaut Syndrome (1993). "Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome". The New England Journal of Medicine 328 (1): 29–33. doi:10.1056/NEJM199301073280105. PMID 8347179.
- Devinsky, O; Faught, RE; Wilder, BJ; Kanner, AM; Kamin, M; Kramer, LD; Rosenberg, A (1995). "Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures". Epilepsy research 20 (3): 241–6. doi:10.1016/0920-1211(94)00084-A. PMID 7796796.
- O'neil, MG; Perdun, CS; Wilson, MB; Mcgown, ST; Patel, S (1996). "Felbamate-associated fatal acute hepatic necrosis". Neurology 46 (5): 1457–9. doi:10.1212/wnl.46.5.1457. PMID 8628501.
- Feucht, M; Brantner-Inthaler, S (1994). "Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study". Epilepsia 35 (5): 993–8. doi:10.1111/j.1528-1157.1994.tb02544.x. PMID 7925171.
- Yagi, K (2004). "Overview of Japanese experience-controlled and uncontrolled trials". Seizure : the journal of the British Epilepsy Association. 13 Suppl 1: S11–5; discussion S16. doi:10.1016/j.seizure.2004.04.018. PMID 15511680.
- Yamauchi, T; Aikawa, H (2004). "Efficacy of zonisamide: our experience". Seizure : the journal of the British Epilepsy Association. 13 Suppl 1: S41–8; discussion S49. doi:10.1016/j.seizure.2004.04.021. PMID 15511689.
- Van Rijckevorsel-Harmant, K; Delire, M; Rucquoy-Ponsar, M (1986). "Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins". European archives of psychiatry and neurological sciences 236 (2): 119–22. doi:10.1007/BF00454021. PMID 3792407.
This page uses Creative Commons Licensed content from Wikipedia. A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.